Scientific Development Committee

Rimi Hazra P

Rimi Hazra, PhD

University of Pittsburgh

Vascular Medicine Institute

Dr. Hazra represents a crucial part of the scientific team at NeuroBiology Foundation where she is focused on developing our scientific strategies for research, and scientific communication initiatives to enhance potential for academic and industrial collaboration. She has a comprehensive knowledge and experience in molecular biology and neurobiology and has a strong interest in globally focused public health research.



Bradley Cooke_szlg

Bradley Cooke, PhD

Georgia State University

Neuroscience Institute

Dr. Cooke has joined the scientific team at NeuroBiology Foundation. Brad received his Ph.D. in Neuroscience and Psychology from UC Berkeley in 2000, and a B.S. in Cognitive Science from Vassar College in 1995. His research focus has been on the development and behavioral significance of neural sex differences, including those that arise through prenatal influences and those that emerge at puberty. He has studied the brain at multiple levels of analysis, from synapses and dendrites to behavior and evolutionary psychology. Recent work has been centered on sex differences in the prevalence of mental illness, including mood disorders and schizophrenia.


Jeremy Ford300w_soft260x380

Jeremy Ford, M.S

University of North Carolina

School of Medicine

Jeremy Ford has joined the scientific team at NeuroBiology Foundation and significantly complements our organization. He received his B.S. from UNC-Chapel Hill and M.S. in Neuroscience from Tulane University. He is currently completing an M.D. and M.B.A. from the UNC School of Medicine and Kenan-Flagler Business School. His research efforts have focused on both basic science and clinical projects in neuroscience, including addiction and pain work in animal models as well as diffusion tensor imaging studies in patients with autism. As a business student, he has worked with both startup and high-growth companies in life sciences and biomedical imaging to craft their commercialization strategies. Mr. Ford’s goal is to identify and develop emerging biomedical technologies with the strongest clinical and market potential so that they may sooner benefit patients living with neuropsychiatric disorders.